Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 188-193 , Summer 2009

Making the Case for Molecular Staging of Malignant Pleural Mesothelioma

  • Raphael Bueno, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Raphael Bueno, MD, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

References 

  1. Pass HI. Malignant pleural mesothelioma: Surgical roles and novel therapies. Clin Lung Cancer. 2001;3:102–117
  2. Sugarbaker DJ, Norberto JJ, Bueno R. Current therapy for mesothelioma. Cancer Control. 1997;4:326–334
  3. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. 626, e1-e3 J Thorac Cardiovasc Surg. 2008;135:620–626
  4. Pass HI, Robinson BW, Testa JR, et al. Emerging translational therapies for mesothelioma. Chest. 1999;116:455S–460S
  5. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993;11:1172–1178
  6. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma (Results in 120 consecutive patients). Ann Surg. 1996;224:288–294, discussion, 294-296
  7. Sugarbaker DJ, Liptay MJ. Therapeutic approaches in malignant mesothelioma. In:  Aisner J,  Arriagada R,  Green MR, et al. editor. Comprehensive Textbook of Thoracic Oncology. Baltimore, MD: Williams and Wilkins; 1996;p. 786–798
  8. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63, discussion, 63-65
  9. Sugarbaker DJ. Macroscopic complete resection: The goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–176
  10. Zellos L, Sugarbaker DJ. Current surgical management of malignant pleural mesothelioma. Curr Oncol Rep. 2002;4:354–360
  11. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137:453–458
  12. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–146
  13. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–1567
  14. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002;62:4963–4967
  15. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003;95:598–605
  16. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:4406–4414
  17. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101:678–686
  18. Toyooka S, Kishimoto T, Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama. 2008;62:1–7
  19. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735
  20. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–965
  21. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: A reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78:1774–1776
  22. Tournoy KG, Burgers SA, Annema JT, et al. Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma. Clin Cancer Res. 2008;14:6259–6263
  23. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80:1988–1992, discussion, 1992-1993
  24. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma (From The International Mesothelioma Interest Group). Chest. 1995;108:1122–1128
  25. Alvarez JM, Ha T, Musk W, et al. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2005;130:905–906
  26. Van Schil P. Malignant pleural mesothelioma: Staging systems. Lung Cancer. 2005;49(suppl 1):S45–S48
  27. van Meerbeeck JP, Boyer M. Consensus report: Pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer. 2005;49(suppl 1):S123–S127
  28. Heelan R. Staging and response to therapy of malignant pleural mesothelioma. Lung Cancer. 2004;45(suppl 1):S59–S61
  29. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14:1–12
  30. Jett JR. Malignant pleural mesothelioma (A proposed new staging system). Chest. 1995;108:895–897
  31. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients (Part 2: Prognosis and staging). Cancer. 1993;72:394–404
  32. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004;10:849–859
  33. Kettunen E, Nissen AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer. 2001;91:492–496
  34. Borczuk AC, Cappellini GC, Kim HK, et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene. 2007;26:610–617
  35. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970–2979
  36. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet. 2006;170:9–15
  37. Christensen BC, Godleski JJ, Marsit CJ, et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis. 2008;29:1555–1559
  38. Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer. 2005;49(suppl 1):S99–S103
  39. Gordon GJ, Deters LA, Nitz MD, et al. Differential diagnosis of solitary lung nodules with gene expression ratios. J Thorac Cardiovasc Surg. 2006;132:621–627
  40. Gordon GJ, Richards WG, Sugarbaker DJ, et al. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev. 2003;12:905–910
  41. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cells. 2004;5:607–616
  42. Ankerst DP, Groskopf J, Day JR, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303–1308, discussion, 1308
  43. Deras IL, Aubin SM, Blase A, et al. 3: A molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–1592
  44. Hofmann HS, Hansen G, Burdach S, et al. Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med. 2004;170:516–519
  45. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  46. van 't Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  47. Reid JF, Lusa L, De Cecco L, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927–930
  48. Muggerud AA, Johnsen H, Barnes DA, et al. Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. BMC Cancer. 2006;6:59
  49. Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 2006;8:R58
  50. Hu M, Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer. 2008;44:2760–2765
  51. Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7
  52. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418–427
  53. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med. 2006;354:2463–2472
  54. Van De Vijver MJ, He YD, Van'T Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  55. Richards W, Van Oss S, Glickman J, et al. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem. 2007;3:1–9

PII: S1043-0679(09)00078-1

doi: 10.1053/j.semtcvs.2009.07.003

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 188-193 , Summer 2009

Article Tools

* Image Usage & Resolution